EAA-Guided AN69-oXiris and PMX-HP Therapy in Septic Patients
A legfontosabb adatok
- Ki végzi
- Kyoung Moo Im
- Hol
- Dél-Korea1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Csak meghívásos
- Résztvevők
- 50 fő, tervezett
- Kezdés
- 2026. aug. 11.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Adsorptive Hemofilter for Continuous Renal Replacement Therapy
- Polymyxin B-Immobilized Hemoperfusion Cartridge
- A regiszteradat frissítve
- 2026. augusztus 26.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 2 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must meet all of the following criteria:; Adults aged 18 years or older; Diagnosis of sepsis or septic shock caused by an intra-abdominal infection, including peritonitis, according to the Sepsis-3 criteria; Completion of emergency surgery for infection source control, with successful surgical control of the infection source; Admission to the surgical intensive care unit (SICU) for postoperative intensive care; Ability to undergo measurement of endotoxin activity (EA) using the Endotoxin Activity Assay (EAA); Determination by a critical care specialist that extracorporeal blood purification therapy with either AN69-oXiris or PMX-HP is clinically indicated; Ability to obtain central venous access and undergo extracorporeal blood purification therapy; Provision of voluntary written informed consent by the participant or the participant's legally authorized representative after receiving sufficient information about the study
Ki nem vehet részt
- Participants meeting any of the following criteria will be excluded:; Younger than 18 years of age; Surgical source control of the infection was not performed or was considered incomplete; Pregnant or breastfeeding; Refusal to participate in the study or inability to obtain informed consent from a legally authorized representative; Concurrent participation in another clinical study
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Sepsis and septic shock are life-threatening conditions in which the body's response to infection can cause dangerously low blood pressure and organ failure. In some patients with an infection inside the abdomen, severe inflammation may continue even after emergency surgery or another procedure has controlled the source of infection. Endotoxin is a substance produced by certain bacteria that may worsen this inflammation. The Endotoxin Activity Assay is a blood test that estimates how strongly endotoxin is affecting the body.
A teljes eredeti leírásKevesebb
This study will compare two blood purification treatments, AN69-oXiris and polymyxin B hemoperfusion (PMX-HP), in patients receiving intensive care for sepsis or septic shock caused by an intra-abdominal infection. Blood purification removes blood through a central venous catheter, passes it through a special filter or cartridge, and then returns it to the body. These treatments are intended to reduce endotoxin or other substances involved in inflammation.
The study plans to enroll 50 participants at Seoul St. Mary's Hospital. Participants will be assigned by chance, in a 1:1 ratio, to receive either AN69-oXiris or PMX-HP. Participants and the clinical team will know which treatment is used.
A vizsgálat 2 csoportja
- AN69-oXirisA vizsgált kezelés
Participants assigned to this arm will receive extracorporeal blood purification using an AN69-oXiris hemofilter through a central venous catheter. Treatment will be administered in sequential cycles during the 72-hour study period, with filter replacement according to the study protocol and the participant's clinical condition. Standard treatment for sepsis or septic shock will continue as clinically indicated.
Kezelés: Adsorptive Hemofilter for Continuous Renal Replacement Therapy
- PMX-HPA vizsgált kezelés
Participants assigned to this arm will receive direct hemoperfusion using a PMX-HP cartridge containing polymyxin B-immobilized fibers through a central venous catheter. Treatment will consist of one or two sessions. When a second session is administered, it will begin approximately 24 hours after initiation of the first session. Standard treatment for sepsis or septic shock will continue as clinically indicated.
Kezelés: Polymyxin B-Immobilized Hemoperfusion Cartridge
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Establishing Evidence Based Application of AN69-oXiris and PMX-HP Therapies Based on the Endotoxin Activity Assay in Septic Patients
- A regiszteradat frissítve
- 2026. augusztus 26.